STERIS
Supplies sterilization equipment, procedural products, and services for healthcare and life-sciences workflows.
Something off on this page? Send us feedback.
Profile
Serves healthcare providers and life-sciences manufacturers with sterilization equipment, procedural products, consumables, maintenance, repair, reprocessing, and contract microbial-reduction services. Healthcare generates most revenue, supported by global Applied Sterilization Technologies and Life Sciences operations.
Supplies hospitals and procedure centers with sterilizers, surgical tables, endoscope reprocessors, consumables, instruments, operating-room connectivity, equipment maintenance, and outsourced instrument reprocessing. Healthcare is the largest segment and generates most revenue; although the business serves customers worldwide, most revenue comes from the United States.
Applied Sterilization Technologies operates a global network that sterilizes medical devices and pharmaceuticals, performs laboratory testing, and supplies integrated sterilization equipment and process controls. Life Sciences provides washers, sterilizers, cleanroom chemistries, water systems, decontamination systems, and maintenance for aseptic manufacturing.
Combines capital equipment with consumables, installation, repair, and outsourced processing across regulated workflows. Operations depend on procedure volumes, regulated product and facility approvals, and access to ethylene oxide and cobalt-60 for contract sterilization.
Company facts
Categories
Key statistics
Year to date −6.6% · Average volume (30d) 688.2K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 28, 2026 | UBS | Initiate | Buy | $275 | ||
| May 21, 2026 | Piper Sandler | Target | $260 | $270 | ||
| May 13, 2026 | Keybanc | Reiterate | Overweight | $265 | $269 | |
| Jul 15, 2025 | Morgan Stanley | Upgrade | Equal Weight | Overweight | ||
| Oct 24, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q1 FY27 | $2.49 | $2.59 | +4.0% | $1.49B | $1.50B | +0.3% | −0.40% |
| May 11, 2026Q4 FY26 | $2.85 | $2.83 | −0.7% | $1.59B | $1.59B | −0.4% | +4.46% |
| Feb 4, 2026Q3 FY26 | $2.53 | $2.53 | 0.0% | $1.48B | $1.50B | +1.0% | −7.74% |
| Nov 5, 2025Q2 FY26 | $2.35 | $2.47 | +5.1% | $1.43B | $1.46B | +2.0% | +6.94% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.48B | $1.39B | $1.46B | $1.50B | $1.59B | $1.49B | |
| Gross profit | $641.2M | $628.0M | $645.9M | $655.5M | $697.1M | $684.2M | |
| Operating income | $216.2M | $246.0M | $268.0M | $271.0M | $316.8M | $285.8M | |
| Net income | $145.7M | $177.4M | $191.9M | $192.8M | $220.3M | $200.1M | |
| Diluted EPS | $1.48 | $1.79 | $1.94 | $1.96 | $2.24 | $2.04 | |
| Gross margin | 43.3% | 45.1% | 44.2% | 43.8% | 43.9% | 45.8% | |
| Operating margin | 14.6% | 17.7% | 18.4% | 18.1% | 19.9% | 19.1% |
Fiscal years (4-quarter sums)FY22 $4.59B · FY23 $4.96B · FY24 $4.84B · FY25 $5.46B · FY26 $5.94B
Revenue by product · Q1 FY27
Revenue by geography · Q1 FY27
Balance sheet, Jun 30, 2026Cash & short-term investments $482.3M · Total debt $2.04B · Total assets $10.74B · Shareholders' equity $7.21B
Dividends
Raised for 19 straight years — most recently to $0.63 from $0.57 in Sep 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 8, 2026 | Jun 8 | Jun 26 | $0.63 | |
| Feb 17, 2026 | Feb 17 | Mar 19 | $0.63 | |
| Nov 18, 2025 | Nov 18 | Dec 18 | $0.63 | |
| Sep 4, 2025 | Sep 4 | Sep 26 | $0.63 | raised from $0.57 |
| Jun 10, 2025 | Jun 10 | Jun 26 | $0.57 | |
| Feb 20, 2025 | Feb 20 | Mar 21 | $0.57 | |
| Nov 19, 2024 | Nov 19 | Dec 19 | $0.57 | |
| Sep 5, 2024 | Sep 5 | Sep 20 | $0.57 | raised from $0.52 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 97.46M · Float 97.13M · 99.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.82M | 9.05% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 6.41M | 6.57% | 13F | Aug 13, 2026 |
| State Street Corp | 5.07M | 5.21% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 5.00M | 5.13% | 13F | Aug 13, 2026 |
| Morgan Stanley | 3.95M | 4.05% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Mohsen Sohi | director | −4,058 | $235.78 |
| Jun 15, 2026 | John Adam Zangerle | officer: Sr. VP, Gen Counsel, and Sec. | −1,419 | $209.28 |
| Jun 5, 2026 | Daniel A. Carestio | director, officer: President and CEO | −1,374 | $212.00 |
| Jun 4, 2026 | Daniel A. Carestio | director, officer: President and CEO | −3,054 | $214.64 |
| Jun 2, 2026 | Richard C. Breeden | director | −1,481 | $209.51 |
Peers
- Sotera Health
Direct AST peer in contract sterilization and lab testing
- Fortive
ASP challenges low-temperature sterilization and reprocessing
- Ecolab
Competes in infection-prevention chemistry and contamination control
- Solventum
Targets sterility assurance and surgical infection prevention
- Stryker
Adjacent rival in surgical instruments and OR workflow
- Boston Scientific
Narrow GI endoscopy rival with infection-prevention products
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| STERIS | $233.78 | +0.06% | $22.78B | 28.6 | 20.4 | 3.8 | +7.8% |
| Sotera Health | $19.27 | 0.00% | $5.50B | 33.7 | 18.7 | 4.5 | +9.2% |
| Fortive | $59.69 | 0.00% | $18.03B | 35.1 | 19.2 | 4.2 | −27.8% |
| Ecolab | $275.05 | −4.11% | $80.70B | 38.5 | 33.2 | 4.8 | +9.7% |
| Solventum | $90.50 | −0.68% | $15.78B | 11.1 | 13.5 | 1.9 | +2.2% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Median | 34.0 | 18.9 | 4.3 | +8.4% |